34.91
price up icon1.01%   0.35
after-market After Hours: 34.91
loading
Royalty Pharma Plc stock is traded at $34.91, with a volume of 3.96M. It is up +1.01% in the last 24 hours and up +2.62% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$34.56
Open:
$34.6
24h Volume:
3.96M
Relative Volume:
0.89
Market Cap:
$14.15B
Revenue:
$2.26B
Net Income/Loss:
$1.09B
P/E Ratio:
14.90
EPS:
2.3431
Net Cash Flow:
$2.70B
1W Performance:
+2.53%
1M Performance:
+2.62%
6M Performance:
+42.66%
1Y Performance:
+32.94%
1-Day Range:
Value
$34.42
$34.99
1-Week Range:
Value
$34.14
$35.38
52-Week Range:
Value
$24.05
$35.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Name
Royalty Pharma Plc
Name
Phone
(212) 883-0200
Name
Address
110 EAST 59TH STREET, NEW YORK, NY
Name
Employee
99
Name
Twitter
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RPRX
Royalty Pharma Plc
34.91 14.15B 2.26B 1.09B 2.70B 2.3431
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
448.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
513.58 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
312.32 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
537.92 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
252.78 28.51B 3.81B -644.79M -669.77M -6.24

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-16-25 Initiated Morgan Stanley Overweight
Jun-03-24 Downgrade UBS Buy → Neutral
Jun-14-22 Resumed UBS Buy
May-13-22 Initiated Scotiabank Sector Outperform
Apr-27-22 Initiated Goldman Buy
Apr-14-22 Upgrade JP Morgan Neutral → Overweight
Apr-06-22 Resumed Morgan Stanley Overweight
Oct-29-21 Upgrade Citigroup Neutral → Buy
Jul-30-21 Initiated Tigress Financial Buy
Nov-09-20 Upgrade UBS Neutral → Buy
Jul-14-20 Initiated Evercore ISI In-line
Jul-13-20 Initiated BofA Securities Buy
Jul-13-20 Initiated Citigroup Neutral
Jul-13-20 Initiated Cowen Outperform
Jul-13-20 Initiated Goldman Neutral
Jul-13-20 Initiated JP Morgan Neutral
Jul-13-20 Initiated Morgan Stanley Equal-Weight
Jul-13-20 Initiated SunTrust Buy
Jul-13-20 Initiated UBS Neutral
View All

Royalty Pharma Plc Stock (RPRX) Latest News

pulisher
Jun 18, 2025

SG Americas Securities LLC Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock? - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Bank Pictet & Cie Europe AG - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Wealth Enhancement Advisory Services LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Wealth Enhancement Advisory Services LLC Acquires New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

(RPRX) Trading Signals - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Short Interest in Royalty Pharma plc (NASDAQ:RPRX) Expands By 39.9% - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

53,487 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by SG Americas Securities LLC - Defense World

Jun 16, 2025
pulisher
Jun 16, 2025

Merit Financial Group LLC Makes New $252,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month HighWhat's Next? - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Has $3.13 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 14, 2025
pulisher
Jun 12, 2025

Royalty Pharma stock hits 52-week high at $34.33 amid robust growth - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Wedge Capital Management L L P NC Buys Shares of 1,014,799 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 12, 2025
pulisher
Jun 10, 2025

Royalty Pharma at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives - Yahoo Finance

Jun 09, 2025
pulisher
Jun 07, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Ameriprise Financial Inc. - MarketBeat

Jun 07, 2025
pulisher
Jun 04, 2025

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

(RPRX) Technical Data - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 03, 2025

Mackenzie Financial Corp Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

California State Teachers Retirement System Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

33,531 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by 111 Capital - MarketBeat

Jun 03, 2025
pulisher
May 31, 2025

Royalty Pharma plc (NASDAQ:RPRX) Stock Position Trimmed by Tidal Investments LLC - MarketBeat

May 31, 2025
pulisher
May 31, 2025

150,344 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by Lansforsakringar Fondforvaltning AB publ - MarketBeat

May 31, 2025
pulisher
May 30, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

GF Fund Management CO. LTD. Invests $238,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 30, 2025
pulisher
May 29, 2025

Squarepoint Ops LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat

May 29, 2025
pulisher
May 28, 2025

Janus Henderson Group PLC Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

University of Texas Texas AM Investment Management Co. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

USS Investment Management Ltd Has $4.14 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 28, 2025
pulisher
May 27, 2025

Quantinno Capital Management LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 27, 2025
pulisher
May 26, 2025

State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Captrust Financial Advisors Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Two Sigma Investments LP Has $61.74 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Worldquant Millennium Advisors LLC Has $15.57 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

May 26, 2025

Royalty Pharma Plc Stock (RPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.56
price down icon 2.13%
$20.16
price up icon 1.56%
$99.46
price down icon 0.82%
$104.40
price down icon 0.54%
biotechnology ONC
$252.78
price down icon 0.52%
Cap:     |  Volume (24h):